EMIS News 0.2163 Emisphere Tech (EMIS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Emisphere Tech (EMIS) 0.2163 $EMIS

Emisphere Technologies, Inc. Announces Financial Results for Fourth Quarter and Year Ended December 31, 2013
GlobeNewswire - Mon Mar 31, 7:13AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced its financial results for the fourth quarter and year ended December 31, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.

Emisphere Technologies, Inc. Announces 2013 Earnings Conference Call
GlobeNewswire - Fri Mar 28, 2:01PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company" announced today that Management will host a conference call to discuss the Company's financial and operational results for the twelve months ended December 31, 2013 on Monday, March 31, 2014 at 8:30 AM ET. A press release will be issued prior to market open.

Echo Therapeutics names Michael M. Goldberg to board
M2 - Mon Mar 03, 6:33AM CST
Us-based medical device company Echo Therapeutics Inc (Nasdaq:ECTE) announced on Friday the appointment of Michael M Goldberg, MD, to the company's board of directors.

Worldwide Oral Proteins and Peptides Market Report 2014 - Forecasts to 2024
M2 - Fri Feb 07, 8:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fdknx/oral_proteins_and) has announced the addition of the "Worldwide Oral Proteins and Peptides Market Report 2014 - Forecasts to 2024" report to their offering. The 'Oral Proteins and Peptides Market, 2014-2024' report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Endogenous peptides are a smart way to utilise body's own resources to design drugs that are more specific and carry great potential to cure hard-to-treat diseases. The protein and peptide therapeutics market is a multi-billion dollar market and researchers are trying their best to improve the therapy by devising strategies for their oral delivery. The report portrays the efforts of various pharmaceutical companies in making the transition towards oral delivery by developing innovative technologies and testing multiple drug candidates based on these technologies. A vast amount of activity is happening in this area as seen by the myriad of discoveries, patents, collaborations and grants. One of the key objectives of this report is to understand the current and future state of the oral proteins and peptide drugs market. This is done by analyzing the following: - Drugs currently available in the market and those under development. - Development and likely sales potential of key marketed and pipeline oral proteins and peptides. - Emerging technologies and key developments supporting the development of improved oral peptide delivery. Key Topics Covered: 1. Executive Summary 1.1. Scope Of The Report 1.2. Research Methodology 1.3. Chapter Outlines 1.4. Key Highlights 1.4.1. Oral Protein And Peptide Market Gained Momentum By The Launch Of Linzess In 2012 1.4.2. Diabetes Dominates The Market 1.4.3. Around 40% Of Molecules Are In The Second Or Higher Phase Of Clinical Development 1.4.4. Sandimmune And Ddavp: Two Oral Peptides Available For More Than A Decade 1.4.5. Gipet And Axcess Are The Most Prominent Technologies 2. Introduction 2.1. Chapter Overview 2.2. Comparison Of Protein / Peptide Drugs With Small Molecule Drugs 2.3. Route Of Administration 2.4. Development Challenges 2.5. Oral Proteins And Peptides 3. Overview And Market Background 4. Drug Profiles And Market Forecast 4.1. Introduction 4.2. Overall Market 4.3. Linaclotide (Linzess / Constella) 4.4. In-105 4.5. Ostora 4.6. Octreolin 4.7. Plecanatide 5. Case Studies: Liprotamase, Sandimmune, Ddavp 5.1. Liprotamase 5.2. Sandimmune 5.3. Ddavp / Minirin (Desmopressin) 6. Technology Platforms 6.1. Chapter Overview 6.2. Gastrointestinal Permeation Enhancement Technology, Gipet (Merrion Pharmaceuticals) 6.3. Eligen (Emisphere Technologies) 6.4. Peptelligence (Enteris Biopharma) 6.5. Oral Antibody Platform (Avaxia Biologics) 6.6. Axcess (Proxima Concepts) 6.7. Multi Matrix System (Cosmo Pharmaceuticals) 6.8. Oramed Pod (Protein Oral Delivery) Technology 7. SWOT Analysis 7.1. Strengths 7.2. Weaknesses 7.3. Opportunities 7.4. Threats 8. Conclusion 8.1. The Rise Of New Technologies 8.2. The Preferred Delivery Mode For A Host Of Indications 8.3. An Emerging Market Close To The Tipping Point 8.4. Challenges Exist, Though These Can Be Surpassed 9. Appendix 1: Tables 10. Appendix 2: List Of Companies For more information visit http://www.researchandmarkets.com/research/5f...oteins_and

Navidea Biopharmaceuticals Adds New Member to Board of Directors
Business Wire - Fri Nov 15, 11:48AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael M. Goldberg, MD, MBA has been appointed to the Navidea Board of Directors.

Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended September 30, 2013
GlobeNewswire - Tue Nov 12, 7:01AM CST
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced its financial results for the quarter ended September 30, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.

Emisphere Technologies, Inc. Announces Third Quarter 2013 Earnings Conference Call
GlobeNewswire - Fri Nov 08, 3:15PM CST
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company" announced today that management will host a conference call to discuss the Company's financial and operational results for the third quarter ended September 30, 2013 on Tuesday, November 12, 2013 at 8:30 AM ET. A press release will be issued prior to market open.

OTC Signal Daily Stock Watch - Emisphere Technologies, Inc., (OTC: EMIS)
WorldStockWire - Wed Sep 11, 11:00PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com

Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended June 30, 2013
GlobeNewswire - Tue Aug 13, 7:01AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced its financial results for the quarter ended June 30, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.

Emisphere Technologies, Inc. Announces Second Quarter 2013 Earnings Conference Call
GlobeNewswire - Thu Aug 08, 4:00PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company" announced today that management will host a conference call to discuss the Company's financial and operational results for the second quarter ended June 30, 2013 on Tuesday, August 13, 2013 at 8:30 AM ET. A press release will be issued prior to market open.

Avitaminosis (Hypovitaminosis) - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m8vpx/avitaminosis) has announced the addition of the "Avitaminosis (Hypovitaminosis) - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for Avitaminosis (Hypovitaminosis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Avitaminosis (Hypovitaminosis). The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Avitaminosis (Hypovitaminosis). - A review of the Avitaminosis (Hypovitaminosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Avitaminosis (Hypovitaminosis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Avitaminosis (Hypovitaminosis) Overview Therapeutics Development An Overview of Pipeline Products for Avitaminosis (Hypovitaminosis) Companies Involved in Avitaminosis (Hypovitaminosis) Therapeutics Development Kyowa Hakko Kirin Co Zeria Pharmaceutical Co Emisphere Technologies Cytochroma Inc Avitaminosis (Hypovitaminosis) - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix For more information visit http://www.researchandmarkets.com/research/9m...itaminosis

Emisphere Technologies, Inc. Announces Financial Results for Quarter Ended March 31, 2013
GlobeNewswire - Wed May 15, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced its financial results for the quarter ended March 31, 2013. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.

Emisphere Technologies, Inc. Announces First Quarter 2013 Earnings Conference Call
GlobeNewswire - Mon May 13, 5:04PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company" announced today that management will host a conference call to discuss the Company's financial and operational results for the first quarter ended March 31, 2013 on Wednesday, May 15, 2013 at 8:30 AM ET. A press release will be issued prior to market open.

Novo Nordisk and EMIS Modify Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 01, 3:18PM CDT
Novo Nordisk and Emispher recently modified their agreement for the development and commercialization of oral formulations of Novo Nordisk's proprietary GLP-1 receptor against candidates.

Emisphere Technologies Inc amends Oral GLP-1 Development License Agreement with Novo Nordisk
M2 - Tue Apr 30, 7:39AM CDT
Biopharmaceutical company Emisphere Technologies Inc (OTC BB:EMIS) said on Monday that it has agreed to amend the Development and License Agreement with Novo Nordisk A/S (NYSE:NVO) for the oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists for the potential treatment of Type 2 diabetes using Emisphere's Eligen technology.

Emisphere Announces Restructuring of MHR Obligations
GlobeNewswire - Mon Apr 29, 7:31AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced that it has reached agreement with MHR Fund Management LLC and its various affiliated funds (collectively "MHR" to restructure the terms of its obligations under various promissory notes issued to MHR.

Emisphere Announces Amendment to Oral GLP-1 Development License Agreement With Novo Nordisk
GlobeNewswire - Mon Apr 29, 7:30AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that it has agreed with Novo Nordisk A/S (NYSE:NVO) to amend the two companies' Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists, which have the potential of treating Type 2 diabetes, using Emisphere's Eligentechnology (the "Oral GLP-1 Development Agreement" .

Genital Herpes - Pipeline Review, H1 2013
M2 - Thu Apr 04, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfc5q6/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H1 2013" report to their offering. 'Genital Herpes - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Herpes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Herpes. Scope - A snapshot of the global therapeutic scenario for Genital Herpes. - A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

Emisphere Technologies Inc falls to net loss of USD1.9m in 2012
M2 - Fri Mar 29, 6:17AM CDT
Biopharmaceutical company Emisphere Technologies Inc (OTCBB:EMIS) announced on Thursday a net loss of USD1.9m (USD0.03 per basic & diluted share) for the year ended 31 December 2012.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 84

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 22

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 165

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 85

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 167

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
Fromm Day Marks 50 Years of Learning and Connection

Updated Category News Views 88

A city proclamation can be fluffy civic confetti, but this one lands differently. San Francisco declared Nov. 14, 2026, Fromm Day as the Fromm Institute for Lifelong Learning marked its 50th anniversary, and the underlying story is sturdier than a ceremonial photo op. A program that began in 1976 expecting roughly 50 people at an open house drew about 150 students in its...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Dynamics of the Automated Sortation System Market

Updated Category News Views 95

The Growth of the Automated Sortation System Market The automated sortation systems market is on a rapid ascent, projected to rise significantly and reach an estimated USD 5.68 billion by 2032. This thriving market, valued at approximately USD 4.00 billion in the previous year, demonstrates a vigorous compound annual growth rate (CAGR) of 3.99% from 2024 to 2032. The...

Continue Reading
Advancing Biopharmaceutical Manufacturing with New Ontologies

Updated Category News Views 148

Introducing Advanced Biopharmaceutical Manufacturing Ontologies In a groundbreaking development for the biopharmaceutical industry, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and Open Applications Group, Inc. (OAGi) have unveiled a set of innovative ontologies aimed at improving data interoperability and analytics. This...

Continue Reading
Illinois Tool Works Prepares for Third Quarter Earnings Call

Updated Category News Views 46

Illinois Tool Works Announces Earnings Webcast Schedule Illinois Tool Works Inc. (NYSE: ITW), a prominent name in global manufacturing, is set to release its third quarter results. The company will issue the results on a Wednesday morning at 7:00 a.m. CDT. Following this important announcement, ITW will host a webcast to discuss the outcomes and insights from their...

Continue Reading
Parry Labs Collaborates with Marines on Advanced Data Solutions

Updated Category News Views 158

Parry Labs Collaborates with Marines on Advanced Data Solutions Parry Labs, a leading defense technology firm known for its innovative hardware and digital infrastructure, has engaged with the United States Marine Corps to explore advanced data transfer techniques. During a recent demonstration involving the Joint Staff J6, Parry Labs worked on the Phantom network gateway...

Continue Reading
Discover Autonomix Medical’s Groundbreaking Presentation at EuroPCR

Updated Category News Views 122

Autonomix Medical's Innovative Contribution to EuroPCR Autonomix Medical, Inc. (NASDAQ: AMIX), a pioneering medical device company, is making waves in the field of interventional cardiology. With a focus on precision nerve-targeted treatments, the company has announced exciting developments that will be showcased in a poster presentation at the renowned EuroPCR. The Event...

Continue Reading